This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3sfi
From Proteopedia
m (Protected "3sfi" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
'''Unreleased structure''' | '''Unreleased structure''' | ||
| - | The entry 3sfi is ON HOLD | + | The entry 3sfi is ON HOLD until Paper Publication |
Authors: Flipo, M., Desroses, M., Lecat-Guillet, N., Villemagne, B., Blondiaux, N., Leroux, F., Piveteau, C., Mathys, V., Flament, M.P., Siepmann, J., Villeret, V., Wohlkonig, A., Wintjens, R., Soror, S.H., Christophe, T., Jeon, H.K., Locht, C., Brodin, P., D prez, B, Baulard, A.R., Willand, N | Authors: Flipo, M., Desroses, M., Lecat-Guillet, N., Villemagne, B., Blondiaux, N., Leroux, F., Piveteau, C., Mathys, V., Flament, M.P., Siepmann, J., Villeret, V., Wohlkonig, A., Wintjens, R., Soror, S.H., Christophe, T., Jeon, H.K., Locht, C., Brodin, P., D prez, B, Baulard, A.R., Willand, N | ||
Description: Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors. | Description: Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors. | ||
Revision as of 06:51, 13 July 2011
Unreleased structure
The entry 3sfi is ON HOLD until Paper Publication
Authors: Flipo, M., Desroses, M., Lecat-Guillet, N., Villemagne, B., Blondiaux, N., Leroux, F., Piveteau, C., Mathys, V., Flament, M.P., Siepmann, J., Villeret, V., Wohlkonig, A., Wintjens, R., Soror, S.H., Christophe, T., Jeon, H.K., Locht, C., Brodin, P., D prez, B, Baulard, A.R., Willand, N
Description: Ethionamide Boosters Part 2: Combining Bioisosteric Replacement and Structure-Based Drug Design to Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors.
